JP2017536407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536407A5 JP2017536407A5 JP2017529774A JP2017529774A JP2017536407A5 JP 2017536407 A5 JP2017536407 A5 JP 2017536407A5 JP 2017529774 A JP2017529774 A JP 2017529774A JP 2017529774 A JP2017529774 A JP 2017529774A JP 2017536407 A5 JP2017536407 A5 JP 2017536407A5
- Authority
- JP
- Japan
- Prior art keywords
- solid dispersion
- formulation
- poly
- hpmcas
- meth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims description 13
- 229920000193 polymethacrylate Polymers 0.000 claims description 13
- 239000006185 dispersion Substances 0.000 claims description 4
- 239000007962 solid dispersion Substances 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 14
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 12
- 238000009472 formulation Methods 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 229960004103 abiraterone acetate Drugs 0.000 claims 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical group C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000006104 solid solution Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 3
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920003149 Eudragit® E 100 Polymers 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196605 | 2014-12-05 | ||
| EP14196605.1 | 2014-12-05 | ||
| PCT/US2015/063671 WO2016090105A1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536407A JP2017536407A (ja) | 2017-12-07 |
| JP2017536407A5 true JP2017536407A5 (enExample) | 2020-04-16 |
| JP6830892B2 JP6830892B2 (ja) | 2021-02-17 |
Family
ID=52006907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529774A Active JP6830892B2 (ja) | 2014-12-05 | 2015-12-03 | 抗癌性組成物 |
Country Status (34)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117663C2 (uk) | 2012-09-26 | 2018-09-10 | Арагон Фармасьютікалз, Інк. | Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози |
| SG11201704267VA (en) | 2014-12-05 | 2017-06-29 | Aragon Pharmaceuticals Inc | Anticancer compositions |
| KR102387089B1 (ko) | 2014-12-05 | 2022-04-14 | 아라곤 파마슈티컬스, 인코포레이티드 | 항암 조성물 |
| BR112020007439A2 (pt) | 2017-10-16 | 2020-10-27 | Aragon Pharmaceuticals, Inc. | antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastática |
| WO2020144647A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Pharmaceutical composition comprising apalutamide dispersed in apple sauce |
| TWI840496B (zh) | 2019-01-30 | 2024-05-01 | 美商艾瑞岡醫藥公司 | 用於治療轉移性去勢敏感性前列腺癌之抗雄性激素 |
| AU2020215177A1 (en) | 2019-01-30 | 2021-08-12 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| CA3160121A1 (en) | 2019-11-04 | 2021-05-14 | Aragon Pharmaceuticals, Inc. | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| TW202228794A (zh) | 2020-09-04 | 2022-08-01 | 美商艾瑞岡醫藥公司 | 用於治療前列腺癌之方法 |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| KR20250157532A (ko) | 2023-03-16 | 2025-11-04 | 바이엘 컨수머 케어 악티엔게젤샤프트 | 호르몬 감수성 전립선암의 생화학적 재발이 있는 환자의 치료를 위한 안드로겐 수용체 길항제 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2265624B (en) | 1992-03-31 | 1995-04-19 | British Tech Group | 17-substituted steroids useful in cancer treatment |
| PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| EP1258254A4 (en) | 2000-02-21 | 2004-02-04 | Takeda Chemical Industries Ltd | COMPOSITIONS FOR DELAYED DELIVERY OF PHYSIOLOGICALLY ACTIVE COMPOUNDS THAT ARE LOW WATER-SOLUBLE, METHOD FOR THE PRODUCTION AND USE THEREOF |
| JP3548566B2 (ja) | 2001-02-27 | 2004-07-28 | アストラゼネカ アクチボラグ | 医薬製剤 |
| WO2002080902A1 (en) | 2001-04-02 | 2002-10-17 | Astrazeneca Ab | Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp |
| BR0210530A (pt) | 2001-06-22 | 2004-06-22 | Pfizer Prod Inc | Composições farmacêuticas de drogas e poìimeros acìdicos neutralizados |
| SE0103424D0 (sv) | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
| BR0307515A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão |
| JPWO2003077827A1 (ja) | 2002-03-19 | 2005-07-14 | 日本新薬株式会社 | 医薬固体分散体の製造方法 |
| AU2003292509B2 (en) | 2003-12-15 | 2007-08-02 | Council Of Scientific And Industrial Research | Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer |
| DK2656842T3 (en) | 2006-03-27 | 2016-11-07 | Univ California | Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES |
| PT2414356E (pt) * | 2009-04-03 | 2015-11-23 | Hoffmann La Roche | Composições de {3-[5-(4-cloro-fenil)-1h-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida do ácido propano-1-sulfónico e utilizações das mesmas |
| CA2787083C (en) | 2010-02-16 | 2018-05-22 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| CN102525876B (zh) * | 2010-12-15 | 2014-03-12 | 西安力邦医药科技有限责任公司 | 阿司匹林固体分散体、其制备方法、药物组合物和用途 |
| AU2012271403C1 (en) | 2011-06-15 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| US20150037407A1 (en) | 2012-03-21 | 2015-02-05 | Emphascience, Inc. | Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy |
| WO2013152342A1 (en) * | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| HUE038082T2 (hu) | 2012-06-07 | 2018-09-28 | Aragon Pharmaceuticals Inc | Androgén receptor modulátor kristályformái |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| MX2015002430A (es) | 2012-08-24 | 2015-06-22 | Dow Global Technologies Llc | Acetato-succinatos de hidroxialquilmetilcelulosa. |
| US9977033B2 (en) | 2012-09-11 | 2018-05-22 | The Board Of Regents Of The University Of Texas System | Methods for assessing cancer recurrence |
| SI3725778T1 (sl) * | 2012-09-11 | 2022-02-28 | Medivation Prostate Therapeutics Llc | Formulacije enzalutamida |
| UA117663C2 (uk) * | 2012-09-26 | 2018-09-10 | Арагон Фармасьютікалз, Інк. | Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| PE20151335A1 (es) | 2013-01-22 | 2015-09-18 | Hoffmann La Roche | Composicion farmaceutica con biodisponibilidad mejorada |
| MX2015013247A (es) | 2013-03-15 | 2016-11-25 | Iceutica Inc | Formulacion de acetato de abiraterona. |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| BR112016002970A2 (pt) | 2013-08-12 | 2017-09-12 | Tokai Pharmaceuticals Inc | biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio |
| US9566280B2 (en) * | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| WO2015118015A1 (en) | 2014-02-05 | 2015-08-13 | Lek Pharmaceuticals D.D. | Solid pharmaceutical compositions of androgen receptor antagonists |
| NZ719654A (en) | 2014-02-06 | 2020-06-26 | Hoffmann La Roche | Interleukin-2 fusion proteins and uses thereof |
| TWI765410B (zh) | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體的用途 |
| SG11201704267VA (en) | 2014-12-05 | 2017-06-29 | Aragon Pharmaceuticals Inc | Anticancer compositions |
| MD3226842T2 (ro) | 2014-12-05 | 2021-03-31 | Aragon Pharmaceuticals Inc | Compoziții anticancer |
| KR102387089B1 (ko) | 2014-12-05 | 2022-04-14 | 아라곤 파마슈티컬스, 인코포레이티드 | 항암 조성물 |
| CN109219437A (zh) * | 2016-06-03 | 2019-01-15 | 阿拉贡药品公司 | 抗癌组合物 |
-
2015
- 2015-12-03 KR KR1020177018243A patent/KR102387089B1/ko active Active
- 2015-12-03 PT PT158203513T patent/PT3226843T/pt unknown
- 2015-12-03 UA UAA201707015A patent/UA123538C2/uk unknown
- 2015-12-03 ES ES21175525T patent/ES3019912T3/es active Active
- 2015-12-03 MA MA41111A patent/MA41111B1/fr unknown
- 2015-12-03 CR CR20170218A patent/CR20170218A/es unknown
- 2015-12-03 US US15/533,229 patent/US10285948B2/en active Active
- 2015-12-03 HU HUE15820351A patent/HUE054935T2/hu unknown
- 2015-12-03 EP EP21175525.1A patent/EP3925598B1/en active Active
- 2015-12-03 MD MDE20170154T patent/MD3226843T2/ro not_active IP Right Cessation
- 2015-12-03 PL PL15820351T patent/PL3226843T3/pl unknown
- 2015-12-03 TW TW104140459A patent/TWI709403B/zh not_active IP Right Cessation
- 2015-12-03 WO PCT/US2015/063671 patent/WO2016090105A1/en not_active Ceased
- 2015-12-03 MX MX2017007206A patent/MX381829B/es unknown
- 2015-12-03 HR HRP20211140TT patent/HRP20211140T1/hr unknown
- 2015-12-03 LT LTEP15820351.3T patent/LT3226843T/lt unknown
- 2015-12-03 SM SM20210454T patent/SMT202100454T1/it unknown
- 2015-12-03 ES ES15820351T patent/ES2883187T3/es active Active
- 2015-12-03 JP JP2017529774A patent/JP6830892B2/ja active Active
- 2015-12-03 AU AU2015358497A patent/AU2015358497B2/en active Active
- 2015-12-03 CN CN201580066235.3A patent/CN106999432A/zh active Pending
- 2015-12-03 EA EA201791251A patent/EA201791251A1/ru unknown
- 2015-12-03 SI SI201531686T patent/SI3226843T1/sl unknown
- 2015-12-03 RS RS20211035A patent/RS62421B1/sr unknown
- 2015-12-03 EP EP15820351.3A patent/EP3226843B1/en active Active
- 2015-12-03 SG SG11201704386VA patent/SG11201704386VA/en unknown
- 2015-12-03 CA CA2969675A patent/CA2969675C/en active Active
- 2015-12-03 DK DK15820351.3T patent/DK3226843T3/da active
- 2015-12-03 MY MYPI2017701986A patent/MY192931A/en unknown
- 2015-12-04 AR ARP150103981A patent/AR102925A1/es unknown
-
2017
- 2017-05-16 IL IL252325A patent/IL252325A0/en unknown
- 2017-05-26 PH PH12017500979A patent/PH12017500979A1/en unknown
- 2017-05-29 CL CL2017001373A patent/CL2017001373A1/es unknown
- 2017-06-02 NI NI201700068A patent/NI201700068A/es unknown
- 2017-06-05 CO CONC2017/0005574A patent/CO2017005574A2/es unknown
-
2019
- 2019-03-19 US US16/357,821 patent/US11224575B2/en active Active
-
2021
- 2021-03-15 US US17/201,811 patent/US11911511B2/en active Active
- 2021-08-13 CY CY20211100730T patent/CY1124504T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536407A5 (enExample) | ||
| JP2017536401A5 (enExample) | ||
| HRP20201902T1 (hr) | Pripravci protiv raka | |
| HRP20211140T1 (hr) | Pripravci protiv raka | |
| JP2017536398A5 (enExample) | ||
| JP5832645B2 (ja) | 医薬剤形又は栄養補助剤形に適したコーティング組成物 | |
| HRP20241719T1 (hr) | Antitumorske smjese | |
| JP2014516080A5 (enExample) | ||
| Turanlı et al. | Development and characterization of methylprednisolone loaded delayed release nanofibers | |
| RU2015128609A (ru) | Перенасыщенные стабилизированные наночастицы для слаборастворимых лекарственных средств | |
| JP2012236837A5 (enExample) | ||
| JP2011178784A5 (enExample) | ||
| KR101902602B1 (ko) | 에탄올의 영향에 대해 내성을 갖는 위 내성 제약 또는 기능식품 조성물 | |
| JP2012153772A5 (enExample) | ||
| JP2014528431A5 (enExample) | ||
| RU2014101227A (ru) | Композиция покрытия, подходящая для фармацевтических или нутрицевтических лекарственных форм | |
| JP2016539953A5 (enExample) | ||
| AR103981A1 (es) | Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención | |
| JP2009215293A5 (enExample) | ||
| PE20181925A1 (es) | Composiciones antineoplasicas | |
| JP2018515506A5 (enExample) | ||
| JP2017526697A5 (enExample) | ||
| HRP20200780T1 (hr) | Formulacija za kontrolirano otpuštanje hidrokortizona | |
| JP5032341B2 (ja) | 部分的に中和されたアニオン性（メタ）アクリラートコポリマー | |
| JP2016536395A5 (enExample) |